<DOC>
	<DOCNO>NCT01947868</DOCNO>
	<brief_summary>This open-label , non-interventional , single-arm , multicenter study real-world population ass clinically symptom improvement quality life ( QoL ) patient locally advance metastatic NSCLC positive EGFR mutation receive EGFR-TKIs first-line treatment . The Primary Objective estimate symptom improvement rate patient locally advance metastatic NSCLC positive EGFR mutation receive EGFR-TKIs first-line treatment . A clinically meaningful improvement define increase baseline 2 point LCS ( Lung Cancer Scales ) Week 4 .</brief_summary>
	<brief_title>Evaluation Symptoms Improvement NSCLC Patients With First-Line Therapy EGFR Tyrosine Kinase Inhibitor</brief_title>
	<detailed_description>The Secondary Objectives : 1 . To estimate symptom improvement rate week 2 12 2 . To estimate mean change baseline overall QoL score use FACT-L instrument LCS score Week 2 , 4 12 . 3 . To estimate proportion patient exhibit LCS change 7 point week 2 , 4 12 . 4 . Subgroup information symptom improvement rate , QoL disease-related symptom score gender , smoke status , smoke pattern , WHO performance , number metastatic site , female/never smoker patient COPD week 2 , week 4 week 12 .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Patients diagnose symptomatic , locally advanced metastatic ( stage IIIb/IV ) NSCLC . Patients positive EGFR mutation Patients prescription EGFRTKI firstline treatment Involvement planning and/or conduct clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>